The inhibition of METTL3 and METTL14 via methyltransferase inhibitors suppressed N-methyladenosine (mA) mRNA modification and enhanced the response to anti-PD-1 therapy in pMMR-MSI-L CRC and melanoma, highlighting the relevance of RNA methylation in adaptive immunity [33]. This evidence concerns the gene PDCD1 and colorectal carcinoma.